Reaching a better understanding of tumor immunogenicity and immunotherapy

Furthering immuno-oncology research and biomarker discovery with NGS

Immuno-Oncology Research

Immuno-oncology is an emerging field that has taken great strides in the fight against cancer, bolstered by a refined understanding of how tumors evade the natural immune response. Leading immuno-oncology researchers are leveraging next-generation sequencing (NGS) to study immunotherapy response factors, discover biomarkers, and apply genomics to personalized immunotherapy.

Research into the mechanisms tumors use to evade the immune response have led to promising therapeutic targets. These therapies boost the ability of the immune system to target cancer, or limit the tumor’s ability to evade the immune response. In addition, NGS can help identify which pathways are activated in the tumor environment and involved in processes such as cancer cell proliferation, survival, invasion, and metastasis.  

Cancer cells and T cells in immunotherapy
Advancing Cancer Immunotherapy Research

See how the high-throughput capability of NGS enables immuno-oncology biomarker identification.

View Infographic
Precision Immunotherapies Using Tumor-Specific HLA Ligands
Immuno-oncology research at Immatics

RNA-Seq and HLA typing are increasing the power and efficiency of a target discovery platform.

Read Interview
Publication Review: Cancer and the Immune System
Cancer and immune system publication review

An overview of peer-reviewed research publications that used Illumina NGS to explore interactions between tumor cells and the immune system. 

Read Review

Swetha Anandhan from MD Anderson Cancer Center studies the mechanisms that bolster the ability of malignant cells to evade checkpoint blockade immunotherapy. Her talk highlights the use of single cell RNA-sequencing to identify a unique population of macrophages in glioblastoma multiforme that persists after treatment with immune checkpoint inhibitors.

View Webinar
Immune Profiling of Human Tumors
RNA-Seq Advantages Immuno-oncology Research Doc

Advantages of RNA-Seq in Immuno-Oncology Research

Transcriptome analysis is helping to advance cancer immunotherapy research. This white paper demonstrates the performance of Illumina TruSeq RNA Exome compared to a hybridization-based digital counting method (Nanostring Technologies) for quantitative analysis of 57 tumor tissue samples.

Read White Paper

Illumina offers several library preparation and sequencing options with access to data analysis options for immuno-oncology research. Streamlined workflows and flexible kit configurations accommodate multiple study designs.

Approximately 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.*

Click on the below to view products for each workflow step.

TruSight Oncology 500

Assay targeting multiple variant types, including tumor mutational burden and microsatellite instability, even from low-quality samples.

TruSeq RNA Exome

The TruSeq RNA Exome library prep kit provides a low-cost solution for analyzing human RNA isolated from limited or low-quality samples, including FFPE.

TruSeq DNA Exome

TruSeq DNA Exome is a cost-effective library preparation and exome enrichment solution.

AmpliSeq for Illumina Immune Response Panel

Targeted RNA expression research panel investigating 395 genes involved in tumor-immune system interactions.

Illumina DNA Prep with Enrichment

On-bead tagmentation chemistry is combined with a simplified, single hybridization protocol to reduce total workflow time.

TruSeq Stranded Total RNA Library Prep Kit

A robust, highly scalable whole-transcriptome analysis solution for a variety of species and sample types.

NovaSeq 6000 System

Flexibility and high throughput for virtually any genome, sequencing method, and scale of project.

NextSeq 550 System

Flexible configurations that support up to 12 exomes per run.

BaseSpace Sequence Hub Apps

User-friendly data analysis apps for RNA-Seq and other common methods.

DRAGEN Bio-IT Platform

Accurate, ultra-rapid analysis of NGS data, on-premise or in the cloud.

Isaac Enrichment App

Uses the Isaac Genome Alignment Software and the Isaac Variant Caller for exome data analysis.

Interested in receiving newsletters, case studies, and information on cancer genomics?
Keeping Pace with Immuno-oncology
Identifying Immunotherapy Resistance Biomarkers

Eliezer Van Allen, MD highlights how NGS can help identify biomarkers of response and resistance to cancer immunotherapy.

View Video
Immuno-Oncology Battle Lines Video
Equipping the Body to Fight Cancer From Within

Recent years have seen an explosion in the translation of immuno-oncology research into new treatment modalities.

View Video
Participant Stratification in Immuno-Oncology
Participant Stratification in Immunotherapy Research

Scientists discuss how advances in immuno-oncology research resulting from NGS help better stratify subjects for clinical trials.

View Webinar
Keeping Pace with Immuno-oncology
Keeping Pace with Immuno-Oncology Research

NGS technology can accelerate biomarker identification and bring down costs for research subject screening and safety monitoring.

View Webinar
Unmasking the Viral Etiology of Cancer and Immune Disease
Unmasking the Viral Etiology of Cancer and Immune Disease

Dr. Emilie Hultin and her team use Illumina sequencers to identify novel HPV types correlated with non-melanoma skin cancers.

Read Interview
Using NGS to Aid the Immune System in Targeting Cancers
Using NGS to Aid the Immune System in Targeting Cancers

An overview of exciting new fields of immunotherapy research, and how NGS helps to move them forward.

Read Application Note
Immuno-oncology Informatics Applications Using NGS
Immuno-Oncology Research Informatics Applications Using NGS

Improved informatics tools enable neoantigen discovery and tumor microenvironment analysis.

View Tech Note

*Data calculations on file. Illumina, Inc., 2015